<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456532</url>
  </required_header>
  <id_info>
    <org_study_id>#9384</org_study_id>
    <nct_id>NCT02456532</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Chronic Hypnotic Use 2</brief_title>
  <acronym>CIS2</acronym>
  <official_title>Risks for Transition From Therapeutic Hypnotic Use to Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal will assess risks for transition from therapeutic hypnotic use to abuse in
      people with insomnia. The investigators will study a hypothesized at-risk sub-population,
      insomniacs with hyperarousal, and compare two hypnotics, a drug with mood effects,
      eszopiclone, versus one without mood effects, zolpidem.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in number capsules chosen: nightly choice of 0, 1, 2, or 3 capsules</measure>
    <time_frame>last two weeks of month1 and 3</time_frame>
    <description>total possible nightly dose limited to upper clinical dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>discontinuation difficulty: nightly choice of 0, 1, 2, or 3 capsules</measure>
    <time_frame>last two weeks of month 6</time_frame>
    <description>instruction to stop nightly hypnotic use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in actigraphic determined sleep time</measure>
    <time_frame>first two weeks of months 1, 3, and 6</time_frame>
    <description>comparing the three treatment arms for hypnotic efficacy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Insomnia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Six months of nightly placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zolpidem CR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Six months of zolpidem cr 12.5 mg nightly use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eszopiclone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Six months of eszopiclone 3 mg nightly use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem CR</intervention_name>
    <arm_group_label>Zolpidem CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <arm_group_label>Eszopiclone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-5 diagnosis of insomnia

        Exclusion Criteria:

          -  acute or unstable medical disease,

          -  current or past history of psychiatric disease, alcoholism or drug abuse, and other
             primary sleep disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy A Roehrs, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System Sleep Disorders Ctr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail Koshorek, BS</last_name>
    <phone>313-916-5179</phone>
    <email>gkoshor1@hfhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>HFHS Sleep Disorders Ctr</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Koshorek, BS</last_name>
      <phone>313-916-5179</phone>
      <email>gkoshor1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Dana Withrow, MHA</last_name>
      <phone>313-916-5302</phone>
      <email>dwithro2@hfhs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Timothy Roehrs, PhD</investigator_full_name>
    <investigator_title>Senior Bioscientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Eszopiclone</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

